Pacific Edge Limited

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Pacific Edge Limited sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 3 currently recruiting 3 completed upper quartile by trial count

Pacific Edge Limited: 6 sponsored US clinical trials, 3 recruiting.

Pacific Edge Limited sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Urothelial Carcinoma, with 3 trials.

Upper-quartile sponsor footprint

Pacific Edge Limited sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Pacific Edge Limited pipeline

3 recruiting of 6 indexed (50% open); 3 completed (50%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Urothelial Carcinoma (3 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pacific Edge Limited: open-pipeline peers nationwide

Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Pacific Edge Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1234567 0%20%40%60%80% Total trials Recruiting share Pacific Edge Limited23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Pacific Edge Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pacific Edge Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Pacific Edge Limited page

6 registered trials is a research-attention snapshot, not an endorsement of Pacific Edge Limited or any single study.

  • 3 of Pacific Edge Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Urothelial Carcinoma is the condition Pacific Edge Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pacific Edge Limited pipeline card: 6 registered trials from official public datasets.Report a data error.